Clinical trial NCT03357614: Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
Official title: Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Complicated Urinary Tract Infections
Lead sponsor: Iterum Therapeutics, International Limited
Sponsor class: INDUSTRY
First posted: 2017-11-30
Enrollment: 1395
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective, phase 3, randomized, multicenter, double-blind, double-dummy study to compare the efficacy and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by ciprofloxacin for the treatment of complicated urinary tract infections (cUTI) in adults.


Eligibility criteria: Inclusion Criteria:

1. Adults ≥18 years of age with more than 24 hours of urinary symptoms attributable to a UTI
2. Able to provide informed consent
3. Clinically documented pyelonephritis or complicated urinary tract infection:

   1. Pyelonephritis with normal anatomy
   2. Complicated UTI as defined by one or more of the following factors:

   i. The presence of an indwelling catheter ii. \>100 mL of residual urine after voiding iii. Neurogenic bladder iv. Obstructive uropathy due to nephrolithiasis, tumor or fibrosis v. Azotemia due to intrinsic renal disease vi. Urinary retention in men possibly due to benign prostatic hypertrophy vii. Surgically modified or abnormal urinary tract anatomy
4. At least two of the following signs or symptoms:

   1. Rigors, chills or fever/hypothermia
   2. Flank pain or pelvic pain
   3. Nausea or vomiting
   4. Dysuria, urinary frequency or urinary urgency
   5. Costovertebral angle tenderness on physical examination
5. A mid-stream urine specimen with:

   1. a dipstick analysis positive for nitrite AND
   2. evidence of pyuria as defined by either: i. a dipstick analysis positive for leukocyte esterase AND/OR ii. at least 10 white blood cells per cubic millimeter on microscopic analysis of unspun urine AND/OR iii. White blood cell count ≥10 cells/high-powered field in urine sediment

Exclusion Criteria

1. Receipt of effective antibacterial drug therapy for complicated urinary tract infection (cUTI) for a continuous duration of more than 24 hours during the previous 72 hours. Patients who have objective documentation of clinical progression of cUTI while on antibacterial drug therapy, or patients who received antibacterial drugs for surgical prophylaxis and then develop cUTI, may be appropriate for enrollment.
2. Subjects with an organism isolated from the urine within the last year known to be resistant to ertapenem
3. Severe structural or functional urinary tract abnormality responsible for an intractable infection which in the opinion of the investigator would require \> 10 days of therapy or post-treatment prophylaxis (eg. patients with chronic vesiculo-ureteral reflux).
4. Uncomplicated UTI
5. Patients with paraplegia/quadriplegia
6. Hypotension with systolic blood pressure \< 90 mm Hg
7. Complicated UTI associated with complete obstruction, emphysematous pyelonephritis, known or suspected renal or perinephric abscess or expected to require surgical intervention (not placement of catheters) to achieve cure
8. Patients with a known history of myasthenia gravis
9. Patients who require concomitant administration of tizanidine or valproic acid
10. Patients with a history of allergy to carbapenems or quinolones or amoxicillin-clavulanate or other beta-lactams, or hypersensitivity to probenecid
11. Renal transplantation
12. Patients requiring dialysis
13. Acute or chronic prostatitis
14. High risk for cUTI caused by Pseudomonas sp. (eg,. history of prior UTI due to Pseudomonas species, recent steroid use, others)
15. Chronic indwelling catheters or stents
16. Ileal loops or vesico-urethral reflux
17. Recent trauma to the pelvis or urinary tract within the prior 30 days
18. History of seizures
19. Patients with a history of blood dyscrasias
20. Patients with a history of uric acid kidney stones
21. Patients with acute gouty attack
22. Patients on chronic methotrexate therapy
23. Females of child-bearing potential who are unable to take adequate contraceptive precautions, have a positive pregnancy test result within 24 hours of study entry, are otherwise known to be pregnant, or are currently breastfeeding an infant.
24. Male subjects must agree to use of an effective barrier method of contraception during the study and for 14 days post treatment
25. Patients known to have a history of liver or kidney disease or neutropenia as defined by the following baseline laboratory criteria:

    * Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \> 3 X Upper Limit of Normal
    * Total bilirubin \> 2 X Upper Limit of Normal
    * Neutropenia (\<1000 cells/mm3)
26. Patients participating in any other clinical study that involved the administration of an investigational medication
27. Patient immunocompromised
28. Patients unlikely to comply with the protocol
29. Patients considered unlikely to survive the 4-week study period or has a rapidly progressive or terminal illness

Primary outcomes:
measure: Percentage of Participants With Overall Success
timeFrame: Day 21 +/- 1 day
Secondary outcomes:
measure: Percentage of Participants With Microbiologic Success
timeFrame: Day 21 +/- 1 day
Other outcomes:
Locations:
city: Bellflower
country: United States
facility: Medical Facility
state: California
city: Chula Vista
country: United States
facility: Medical Facility
state: California
city: La Mesa
country: United States
facility: Medical Facility
state: California
city: La Palma
country: United States
facility: Medical Facility
state: California
city: Torrance
country: United States
facility: Medical Facility
state: California
city: Miami Lakes
country: United States
facility: Medical Facility
state: Florida
city: Columbus
country: United States
facility: Medical Facility
state: Georgia
city: Idaho Falls
country: United States
facility: Medical Facility
state: Idaho
city: Boston
country: United States
facility: Medical Facility
state: Massachusetts
city: Royal Oak
country: United States
facility: Medical Facility
state: Michigan
city: Butte
country: United States
facility: Medical Facility
state: Montana
city: Columbus
country: United States
facility: Medical Facility
state: Ohio
city: Columbus
country: United States
facility: Medical Facility
state: Ohio
city: Dallas
country: United States
facility: Medical Facility
state: Texas
city: Houston
country: United States
facility: Medical Facility
state: Texas
city: Kohtla-Järve
country: Estonia
facility: Medical Facility
city: Tallinn
country: Estonia
facility: Medical Facility
city: Võru
country: Estonia
facility: Medical Facility
city: Tbilisi
country: Georgia
facility: Medical Facility
city: Tbilisi
country: Georgia
facility: Medical Facility
city: Tbilisi
country: Georgia
facility: Medical Facility
city: Baja
country: Hungary
facility: Medical Facility
city: Budapest
country: Hungary
facility: Medical Facility
city: Nagykanizsa
country: Hungary
facility: Medical Facility
city: Nyiregyhaza
country: Hungary
facility: Medical Facility
city: Szentes
country: Hungary
facility: Medical Facility
city: Tatabánya
country: Hungary
facility: Medical Facility
city: Daugavpils
country: Latvia
facility: Medical Facility
city: Liepāja
country: Latvia
facility: Medical Facility
city: Riga
country: Latvia
facility: Medical Facility
city: Riga
country: Latvia
facility: Medical Facility
city: Valmiera
country: Latvia
facility: Medical Facility
Study officials:
References:
citation: Dunne MW, Aronin SI, Das AF, Akinapelli K, Breen J, Zelasky MT, Puttagunta S. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2023 Jan 6;76(1):78-88. doi: 10.1093/cid/ciac704.